Revolution Medicines

Revolution Medicines

RVMD· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +82.1% in FY2025

Mark A. Goldsmith, M.D., Ph.D. is the CEO of Revolution Medicines and was paid $14.7M in FY2025 (Dec), up 46%.

Pay$100 in the stock at the end of FY20 → $201
CEO pay is from each Revolution Medicines proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Mark A. Goldsmith, M.D., Ph.D.FY2025
  2. 2Steve Kelsey, M.D., FRCP, FRCPathFY2025
  3. 3Margaret Horn, J.D.FY2025
  4. 4Jeffrey CisliniFY2025
  5. 5Jack AndersFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Revolution Medicines paid its 5 named executives $32.8M in total in FY2025 (Dec). CEO Mark A. Goldsmith, M.D., Ph.D. was paid $14.7M of that.

Name
Mark A. Goldsmith, M.D., Ph.D.President and Chief Executive Officer
Steve Kelsey, M.D., FRCP, FRCPathPresident, Research and Development
Margaret Horn, J.D.Chief Operating Officer
Jeffrey CisliniGeneral Counsel and Secretary
Jack AndersChief Financial OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Revolution Medicines names 17 peer companies for pay. Among Revolution Medicines and these peers, CEO pay was 2nd highest of 5 and total shareholder return was 3rd highest of 5.

2nd highest of 5in Revolution Medicines and its pay peers, FY2025 (Dec) by CEO pay:

$7.7M$19.2M

3rd highest of 5in Revolution Medicines and its pay peers, FY2025 (Dec) by total shareholder return:

$34$524

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Alexis BorisyLead independent director · 10 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    Revolution Medicines CEO pay rose 46% to $14.7M. The stock rose 82% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Revolution Medicines General counsel pay rose 36% to $3.7M. The stock rose 82% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Revolution Medicines COO pay rose 11% to $4.9M. The stock rose 53% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Revolution Medicines Division head pay rose 35% to $5.9M. The stock rose 53% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Revolution Medicines Division head pay rose 80% to $3.2M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  6. Pay
    Revolution Medicines Division head pay fell 17% to $1.8M. The stock fell 5% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Revolution Medicines CEO pay rose 44% to $10.4M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Revolution Medicines COO pay rose 43% to $4.4M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Revolution Medicines CFO pay rose 56% to $3.0M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Revolution Medicines CFO pay rose 29% to $1.9M. The stock fell 5% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Revolution Medicines Division head pay rose 43% to $4.4M. The stock rose 20% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KFeb 25, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 26, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data